| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14712598.2014.871256 |
| P698 | PubMed publication ID | 24387632 |
| P50 | author | David A. Isenberg | Q42326409 |
| P2093 | author name string | Zozik Fattah | |
| P2860 | cites work | Peptide-based approaches to treat lupus and other autoimmune diseases | Q38021184 |
| Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions | Q38460505 | ||
| Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study | Q38466691 | ||
| Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab | Q40260827 | ||
| Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid | Q40265943 | ||
| Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry | Q42661986 | ||
| Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). | Q42748093 | ||
| The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial | Q43038371 | ||
| Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus | Q43064210 | ||
| Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. | Q43472878 | ||
| Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial | Q43481756 | ||
| Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. | Q43699030 | ||
| The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation | Q43890768 | ||
| Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide | Q43993205 | ||
| Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period | Q44520690 | ||
| Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study | Q44623048 | ||
| Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual. | Q44699349 | ||
| Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. | Q45943683 | ||
| A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients | Q46067913 | ||
| Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis | Q46818795 | ||
| Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. | Q50563149 | ||
| B cell biomarkers of rituximab responses in systemic lupus erythematosus. | Q51007054 | ||
| Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. | Q51386995 | ||
| Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. | Q51835763 | ||
| Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies | Q56774177 | ||
| Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus | Q57316195 | ||
| Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus | Q58192318 | ||
| BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 | ||
| Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator | Q28183674 | ||
| Ocrelizumab: a step forward in the evolution of B-cell therapy | Q28245986 | ||
| BAFF, APRIL and their receptors: structure, function and signaling | Q28258238 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors | Q29615065 | ||
| Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes | Q33336433 | ||
| Lupus erythematosus in the 1980s: a survey of 570 patients | Q33384712 | ||
| Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience | Q33388044 | ||
| The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide | Q33401164 | ||
| Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study | Q33527462 | ||
| Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively | Q33561741 | ||
| The central and multiple roles of B cells in lupus pathogenesis | Q33713303 | ||
| Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy | Q33973488 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study | Q34017775 | ||
| Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. | Q34063153 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading? | Q34332377 | ||
| Treatment of systemic lupus erythematosus with epratuzumab. | Q34580559 | ||
| Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial | Q34600950 | ||
| A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses | Q34778834 | ||
| Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus | Q34802966 | ||
| Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-gamma and anti-double-stranded DNA antibody production | Q34897236 | ||
| Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus | Q34897437 | ||
| Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis | Q34975939 | ||
| Type I interferon correlates with serological and clinical manifestations of SLE | Q35555038 | ||
| Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice | Q35835882 | ||
| Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 | ||
| Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance | Q36041818 | ||
| Novel treatments for systemic lupus erythematosus | Q36059553 | ||
| Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. | Q36085018 | ||
| A checkpoint for autoreactivity in human IgM+ memory B cell development | Q36228316 | ||
| Rituximab: a promising therapy in systemic lupus erythematosus | Q36336256 | ||
| Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice | Q36370602 | ||
| Defective B cell tolerance checkpoints in systemic lupus erythematosus | Q36402748 | ||
| Taming lupus-a new understanding of pathogenesis is leading to clinical advances | Q36712941 | ||
| Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study | Q36844513 | ||
| IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model | Q37125180 | ||
| Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus | Q37333433 | ||
| A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus | Q37378350 | ||
| Lupus: novel therapies in clinical development | Q37990100 | ||
| B-cell targeted treatments for lupus: the journey counts as much as the destination | Q38000391 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| P304 | page(s) | 311-326 | |
| P577 | publication date | 2014-01-06 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies | |
| P478 | volume | 14 |
| Q38799791 | Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser |
| Q47550170 | Delayed onset of autoreactive antibody production and M2-skewed macrophages contribute to improved survival of TACI deficient MRL-Fas/Lpr mouse |
| Q37324772 | Drugs in early clinical development for Systemic Lupus Erythematosus |
| Q38747383 | Emerging therapies in systemic lupus erythematous: from clinical trial to the real life |
| Q38539811 | Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies |
| Q37464013 | Interferon (IFN)-λ is a potential mediator in lupus nephritis |
| Q36806630 | Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus |
| Q38271939 | Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. |
| Q38590248 | What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy? |
Search more.